Focused On-demand Library for AP-2 complex subunit mu

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q96CW1

UPID:

AP2M1_HUMAN

Alternative names:

AP-2 mu chain; Adaptin-mu2; Adaptor protein complex AP-2 subunit mu; Adaptor-related protein complex 2 subunit mu; Clathrin assembly protein complex 2 mu medium chain; Clathrin coat assembly protein AP50; Clathrin coat-associated protein AP50; HA2 50 kDa subunit; Plasma membrane adaptor AP-2 50 kDa protein

Alternative UPACC:

Q96CW1; A6NE12; D3DNT1; P20172; P53679

Background:

The AP-2 complex subunit mu, known by various names such as Adaptin-mu2 and Clathrin assembly protein complex 2 mu medium chain, plays a pivotal role in the adaptor protein complex 2 (AP-2). This complex is integral to protein transport via vesicles in different membrane traffic pathways, including clathrin-dependent endocytosis, where it aids in cargo selection and vesicle formation. AP-2 is crucial for receptor-mediated endocytosis and synaptic vesicle membrane recycling, recognizing specific motifs within transmembrane cargo molecules.

Therapeutic significance:

Given its involvement in Intellectual developmental disorder, autosomal dominant 60, with seizures, understanding the role of AP-2 complex subunit mu could open doors to potential therapeutic strategies. Its function in synaptic vesicle recycling and endocytosis underscores its potential as a target in neurological disorders.